

REFERENCES

1. **Adamis AP, Altaweel M and Bressler NM.** Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. *Ophthalmology*. 2006; 113:23-28.
2. **Adamis AP, Miller JW, Bernal MT, D'Amico DJ, Folkman J, Yeo TK and Yeo KT.** Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. *Am J ophthalmol*. 1994; October 118: 445-450.
3. **Adamis Ap, Shima DT, Tolentino M, Gragoudas ES, Ferrara N and Folkman J.** Inhibition of vascular endothelial growth factor prevent retinal ischaemia-associated iris neovascularization in primate. *Arch Ophthalmol*. 1996; 114: 66 - 71.
4. **Aiello LP and Wong JS.** Role of Vascular endothelial growth factor in diabetic vascular complications. *Kidney Int* 2000; 58 (Suppl 77): 113-119.
5. **Aiello LP, Cavallerano J and Bursell S.** Diabetic eye disease. *Endocrinol Metab Clin North Am*. 1996; 25:271–291.
6. **Aiello LP, Gardner TW, King GL, Blankenship G, Cavallerano ID and Ferris III FL.** Diabetic retinopathy. *Diabetes Care*. 1998; 21: 143 - 156.
7. **Akiyama H, Tanaka T, Itakura H, Kanai H, Maeno T, Doi H, Yamazaki M, Takahashi K, Kimura Y, Kishi S and Kurabayashi M.** Inhibition of ocular angiogenesis by an adenovirus carrying the human von Hippel-Lindau tumor-suppressor gene in vivo. *Invest Ophthalmol Vis Sci*. 2004; 45:1289–1296.
8. **Alfredo Pece, Vincenzo Isola and Lucia Vitale.** Management of Choroidal Neovascularization in Myopic Macular Degeneration. *Expert Rev Ophthalmol*. 2008; 3(3):311-323.

References

9. **Alton T, Hemo J, Itin A, PelerJ, Stone J and Keshet F.** Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. *Med.* 1995; 1: 1024 - 1028.
10. **Alzaid AA, Dinneen SF, Melton LJ and Rizza RA.** The role of growth hormone in the development of diabetic retinopathy. *Diabetis Care.* 1994; 17: 531-534.
11. **Ambati J, Gragoudas E, Miller JW, You TT, Miga-Motok and Delori FC.** Trans-scleral delivery of bioactive protein to the choroid and retina. *Invest Ophthalmol Vis Sci* 2000; 41: 1186 - 91.
12. **Anders Kvanta.** Ocular angiogenesis. The role of growth factors. *Acta Ophthalmol. Scand.* 2006; 84: 282–288.
13. **Ashton N.** Studies of the retinal capillaries in relation to diabetes and other retinopathy. *Br J Ophthalmol.* 1963; 47:521-538. In **Bijsterveld OPV.** Diabetic retinopathy. Martin Dunitz Ltd. 2000; Ch. 13: 171- 172.
14. **Ashton N.** Vascular basement membrane changes in diabetic retinopathy. *Br J Ophthalmol.* 1974; 58:344-366. In **Bijsterveld OPV.** Diabetic retinopathy. Martin Dunitz Ltd. 2000; Ch. 13:173.
15. **Au Eong KG, Pieramici DJ, Fujii GY et al.** Macular translocation: unifying concepts, terminology, and classification. *Am. J. Ophthalmol.* 2001; 131(2), 244-253.
16. **Augustin AJ, D’Amico DJ, Mieler WF, Schneebaum C and Beasley C.** Safety of posterior juxtascleral depot administration of the angiostatic cortisone anecortave acetate for treatment of subfoveal choroidal neovascularisation in patients with age-related macular degeneration. *Graefes Arch Clin Exp Ophthalmol.* 2005; 243:9–12.
17. **Bardenstein DS, Char DH, Irvine AR et al.** Extramacular disciform lesions simulating uveal tumors. *Ophthalmology.* 1992; 99:944–951.

References

18. **Bartz-Schmidt KU, Thumann G, Psychias A, Krieglstein GK and Heimann H.** Pars plana vitrectomy, endolaser coagulation of the retina and the ciliary body combined with silicone oil endotamponade in the treatment of uncontrolled neovascular glaucoma. *Graefes Arch Clin Exp Ophthalmol.* 1999; 237:969-975.
19. **Behzadian MA, Bartoli M, El-Remessy AB, Al-Shabrawey M, Platt DH, Liou GI, Caldwell RW and Caldwell RB.** CELLULAR AND MOLECULAR MECHANISMS OF RETINAL ANGIOGENESIS. In: *Retinal and Choroidal Angiogenesis.* J.S.Penn (Ed). Vanderbilt University Scholl of Medicine, Nashville, TN, U.S.A. 2008; pp 1-39.
20. **Bell D, Yang HK and O'Brien C.** A case of bilateral cavernous hemangioma associated with intracerebral hemangioma. *Arch Ophthalmol.* 1997; 115:818–819.
21. **Benelli U, Bocci G, Danesi R, Lepri A, Bernardini N and Bianchi F.** The heparan sulfate sulferoxide inhibits rat corneal angiogenesis and in vitro neovascularization. *Exp Eye Res.* Aug 1998; 67(2):133-142.
22. **Betsholtz C, Lindblom P and Gerhardt H.** Role of pericytes in vascular morphogenesis. *EXS.* 2005; 94: 115–125.
23. **Bian F, Zhang MC and Zhu Y.** Inhibitory effect of curcumin on corneal neovascularization in vitro and in vivo. *Ophthalmologica.* 2008; 222(3):178-186.
24. **Bijsterveld O V.** Diabetic retinopathy. Martin Dunitz Ltd 1st ed. 2000; Ch. 1: 1-22.
25. **Bossi E and Koerner F:** Retinopathy of prematurity. *Intens Care Med.* 1995; 21:241–246.
26. **Boulton M, Gregor Z, McLeod D, Charteris D, Evans J, Moriarty P, Khliq A, Forman D, Allamy D and Bardsley B.** Intravitreal growth

References

- factors in proliferative diabetic retinopathy: correlation with neovascular activity and glycaemic management. *Br J Ophthalmol.* 1997; 81: 228-233.
- 27.**Brancato R, Menchini U, Pece A et al.** Dye laser photocoagulation of macular subretinal neovascularization in pathological myopia. A randomised study of three different wavelengths. *Int. Ophthalmol.* 1988; 11, 235-238.
- 28.**Brancato R, Trabucchi G, Introini U et al.** Indocyanine green angiography (ICGA) in pathological myopia. *Eur. J. Ophthalmol.* 1996; 6, 39-43.
- 29.**Breier G, Albrecht U, Sterrer S and Risau W.** Expression of Vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. *Development.* 1992; 114:521-532.
- 30.**Bressler NM.** Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization – verteporfin in photodynamic therapy report 2. *Am J Ophthalmol.* 2002; 133(1):168–9.
- 31.**Brooks SE, Johnson M, Wallace DK et al.** Treatment outcome in felloweyes after laser photocoagulation for retinopathy of prematurity. *Am J Ophthalmol.* 1999; 127:56–61.
- 32.**Brown LF, Detmar M, Claffey K, et al.** Vascular permeability factor/vascular endothelial growth factor: A multifunctional angiogenic cytokine. 1997; 79, 233-269.
- 33.**Browning DJ, Scott AQ, Peterson CB, Warnock J and Zhang Z.** The risk of missing angle neovascularisation by omitting screening gonioscopy in acute retinal vein occlusion. *Ophthalmology.* 1998; 105:776–784.

References

- 34.**Browning DJ.** Risk of missing angle neovascularization by omitting screening gonioscopy in patients with diabetes mellitus. *Am J Ophthalmol.* 1991; 112-212.
- 35.**Cai W, Rook SL, Jiang ZY, Takahara N and Aiello LP.** Mechanisms of hepatocyte growth factor-induced retinal endothelial cell migration and growth. *Invest Ophthalmol Vis Sci.* 2000; 41: 1885–1893.
- 36.**Campochiaro P A.** Pathogenic mechanisms in proliferative diabetic retinopathy. *Arch Ophthalmol.* 1997; 115: 137-141.
- 37.**Campochiaro PA; C99-PKC412-003 Study Group.** Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. *Invest Ophthalmol Vis Sci.* 2004; 45:922-931.
- 38.**Cardoso RD and Brockhurst RJ.** Perforating diathermy coagulation for retinal angiomas. *Arch Ophthalmol.* 1976; 94:1702–1715.
- 39.**Carmeliet P.** Angiogenesis in life, disease and medicine. *Nature* 2005; 438:932-936.
- 40.**Carr RE and Noble KG** Retinal angiomatosis. *Ophthalmology.* 1980; 87:956–961.
- 41.**Castellon R, Hamdi H, Sacerio I , Aoki A, Kenney M and Alexander V.** Effect of angiogenic growth factors combinations on retinal endothelial cells. *Exp Eye Res.* 2002; 74: 523-535.
- 42.**Central Retinal Vein Occlusion Study Group.** Baseline and early natural history report. The Central Retinal Vein Occlusion Study. *Arch Ophthalmol.* 1993; 11:1087–1095.
- 43.**Chalam KV, Gandham S, Gupta S, Tripathi BJ and Tripathi RC.** Pars plana modified Baerveldt implant versus neodymium: YAG cyclophotocoagulation in the management of neovascular glaucoma. *Ophthalmic Surg Lasers.* 2002; 33:383– 393.
- 44.**Chang JH, Gabison EE, Kato T, et al.** Corneal neovascularization. *Curr Opin Ophthalmol* 2001; 12(4): 242-249.

References

- 45.**Chang M. A. and Green W. R.** Vascular Tumors of the Retina: Histopathology of Retinal Vascular Tumors and Selected Vascular Lesions. In Retinal Vascular Disease. A.M. Jousseaume · T.W. Gardner · B. Kirchhof · S.J. Ryan (Eds.) 2007; Ch. 28.1:735-748.
- 46.**Charache S.** Eye disease in sickling disorders. Hematol Oncol Clin North Am. 1996; 10:1357–1362.
- 47.**Chen TC, Ahn Yuen SJ, Sangalang MA, Fernando RE and Leuenberger EU.** Retrobulbar chlorpromazine injections for the management of blind and seeing painful eyes. J Glaucoma. 2002; 11:209–213.
- 48.**Choyke PL, Glenn GM, Walther MM et al.** von Hippel- Lindau disease: genetic, clinical, and imaging features. Radiology. 1995; 146:629–642.
- 49.**Clark AF and Yorio T.** Ophthalmic drug discovery .Nat Rev Drug Discov 2003; 2:448-459.
- 50.**Clark AF, Challa JK, Danis R and Yorio T.** Inhibition of intraocular tumor by topical application of the angiogenic steroid anecortave acetate. Invest Ophthalmol Vis Sci 1999;40:2158-2162
- 51.**Cohen SY, Laroche A, Leguen Y, Soubrane G and Coscas GJ.** Etiology of choroidal neovascularization in young patients. Ophthalmology. 1996; 103:1241–1244.
- 52.**Colby KA and Adamis AP.** Prevalence of corneal neovascularization in a general eye service population (abstract). Invest Ophthalmol Vis Sci. 1996; 37 (Suppl):S593.
- 53.**Committee on Fetus and Newborn.** Vitamin E and the prevention of retinopathy of prematurity. Pediatrics. 1985; 76:315–316.
- 54.**Connolly DT.** Vascular permeability factor. Unique regulator of blood vessel function. J Cell Biochem. 1991; 47: 219-223.

References

55. Cryotherapy for Retinopathy of Prematurity Cooperative Group. **Palmer EA, Hardy RJ, Dobson V et al.** 15-year outcomes following threshold retinopathy of prematurity: final results from the multicenter trial of cryotherapy for retinopathy of prematurity. *Arch Ophthalmol.* 2005; 123:311–318.
56. **Cunningham ET Jr, Adamis AP, Altaweel M, et al.** A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. *Ophthalmology.* 2005; 112:1747-1757.
57. **Cunningham ET, Adams AP, Altaweel μ , Aillo LP, D'Amico DJ, Bresseler NM, Goldbaum M, GuyerKatz B and Schwartz SD.** Macugen diabetic retinopathy study group. A phase II randomized double-masked trial of pegaptanib, an anti-VEGF aptamer, for diabetic macular edema. *Ophthalmology* 2005 Oct; 112(10):1747-1757.
58. **Custer PL and Reistad CE.** Enucleation of blind, painful eyes. *Ophthalmic Plast Reconstr Surg.* 2000; 16:326–329.
59. **D COSGROVE.** Angiogenesis imaging – ultrasound. *The British Journal of Radiology.* 2003; 76, S43–S49.
60. **D'Amato RJ, Loughnan MS, Flynn E and Folkman J.** Thalidomide is an inhibitor of angiogenesis. *Proc Natl Acad Sci U S A.* Apr 26 1994; 91(9):4082-4085.
61. **Davidorf FH, Mouser JG and Derick RJ.** "Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection." *Retina.* 2006; Mar 26(3):354-356.
62. **Davis M D and Blodi B A.** Proliferative diabetic retinopathy. In Rayan S. *Retina.* Mosby Inc 3rd ed. 2001; vol 2: 1309-1349.

References

- 63.**Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W and Bouck NP.** Pigment epithelium derived factor: a potent inhibitor of angiogenesis. *Science*. 1999; 285:245–248.
- 64.**De Vree WJ, Essers MC, Koster JF and Sluiter W.** Role of interleukin 1 and granulocyte colony stimulating factor in photofrin-based photodynamic therapy of rat rhabdomyosarcoma tumors. *Cancer Res*. 1997; 57:2555–2558.
- 65.**Diabetes Control and Complications Trial Research Group.** The effect of intensive diabetic treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. *Arch Ophthalmol*. 1995; 113:36-51.
- 66.**Diabetic Retinopathy Study Research Group.** Photocoagulation treatment of proliferative diabetic retinopathy: clinical application of Diabetic Retinopathy Study findings: DRS Report 8. *Ophthalmology*. 1981; 88:583-600.
- 67.**Diabetic Retinopathy Vitrectomy Study Research Group.** Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two-year results of a randomized trial. *Diabetic Retinopathy Vitrectomy Study report 2. Arch Ophthalmol*. 1985; 103:1644-1652.
- 68.**Dobyns WB, Michels VV, Groover RV, Mokri B, Trautmann JC, Forbes GS and Laws ER Jr.** Familial cavernous malformations of the central nervous system and retina. *Ann Neurol*. 1987; 21:578–583.
- 69.**Dougherty TJ, Gomer CJ, Henderson B, Jori G, Kessel D, Korbelyik M, Moan J and Peng Q.** Photodynamic therapy. *J Natl Cancer Inst*. 1998; 90:889–905.
- 70.**Duh E, Yang H, Haller IA , Juan E, Humayn MS, Peter G, Melia M, Pieramici D, Harlan J, Campachiaro A and Zack D.** Vitreous levels of pigment epithelial derived factor and vascular endothelial growth factor.

References

- Implications for ocular angiogenesis. *Am J Ophthalmol*. 2004; 137: 668-674.
- 71.**Efron N**. Vascular response of the cornea to contact lens wear. *J Am Optom Assoc*. 1987; 58:836–846.
- 72.**Eid TE, Katz LJ, Spaeth GL and Augsburger JJ**. Tube shunt surgery versus neodymium: YAG cyclophotocoagulation in the management of neovascular glaucoma. *Ophthalmology*. 1997; 104:1692–1700.
- 73.**Enge M, Bjarnegard M, Gerhardt HC et al**. Endothelium-specific platelet derived growth factor-B ablation mimics diabetic retinopathy. *EMBO J*. 2002; 16: 4307– 4316.
- 74.**Epstein RJ, Stulting RD, Hendricks RL and Harris DM**. Corneal neovascularization: pathogenesis and inhibition. *Cornea*. 1987; 6: 250–257.
- 75.**Ferrara N, Houck K, Jakeman L and Leung DW**. Molecular and biological properties of the vascular endothelial growth factor family of proteins. *Endocr Rev*. 1992; 13: 18-32.
- 76.**Ferris F L**. Early photocoagulation in patients with either type 1 or type 11 diabetes. *Trans Am Ophthalmol Soc*. 1996; 94: 500 – 537.
- 77.**Fingar VH**. Vascular effects of photodynamic therapy. *J Clin Laser Med Surg*. 1996; 14:323–328.
- 78.**Fintak DR, Shah GK, Blinder KJ, et al**. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. *Retina*. 2008; 28(10):1395-1399.
- 79.**Folkman J**. Tumour angiogenesis In Mendelsohn PM, Howley M A, Liotta L A. *The molecular basis of cancer*. Philadelphia Sounder 1st ed. 1995; 206-232.

References

- 80.**Foulks GN, Steffanson E and Hamilton RC.** Regression of corneal vascularization during silicone contact lens wear and the relationship to contact lens-induced anterior chamber hypoxia. *Cornea*. 1987; 65:6-60.
- 81.**Frank R N.** Aetiologic mechanism in diabetic retinopathy. In Rayan S. *Retina*. Mosby Inc 3rd ed. 2001; vol 2: 1259 – 1294.
- 82.**Freyberger H, Brocker M, Yakut H, Hammer J, Effert R, Schifferdecker E, Schatz H and Derwahl M.** Increased levels of platelet-derived growth factor in vitreous fluid of patients with proliferative diabetic retinopathy. *Exp Clin Endocrinol Diabetes*. 2000; 108: 106–109.
- 83.**Funatsu H, Yamashita H, Nakamura S, et al.** Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema. *Ophthalmology*. 2006; 113:294-301.
- 84.**Funatsu H, Yamashita H, Noma H, Mochizuki H, Mimura T, Ikeda T and Hori S.** Outcome of vitreous surgery and the balance between Vascular endothelial growth factor and Endostatin. *Invest Ophthalmol Vis Sci*. 2003(4); 44:1042-1047.
- 85.**Galinos SO, Smith TR and Brockhurst RJ.** Angioma-like lesion in hemoglobin sickle cell disease. *Ann Ophthalmol*. 1979; 11:1549–1552.
- 86.**Genaidy M, Kazi AA, Peyman GA, Paissos-Machado E, Farahat HG, Williams JI, Holroyd KJ and BlakeDA.** Effect of squalamine on iris neovascularisation in monkeys. *Retina*. 2002; 22:772–778.
- 87.**Goldberg MF.** Classification and pathogenesis of proliferative sickle retinopathy. *Am J Ophthalmol*. 1971; 71:649–665.
- 88.**Green WR and Wilson DJ.** Choroidal neovascularization. *Ophthalmology*. 1986; 93:1169–1176.

References

- 89.**Green WR.** The uveal tract. In Spencer WH (Ed). *Ophthalmic Pathology. An Atlas and Textbook.* Philadelphia. WB Saunders. 1986; pp 1513–1521.
- 90.**Haas HL and Madri JA.** Extracellular matrix and driven matrix metalloproteinase production in endothelial cells. Implication for angiogenesis. *Trends Cardiovasc Med.* 1999; 9: 70-77.
- 91.**Haller JA, Knox DL.** Vitrectomy for persistent vitreous hemorrhage from a cavernous hemangioma of the optic disc. *Am J Ophthalmol.* 1993; 116: 106-107.
- 92.**Hammes H-P, Lin J, Renner O, Shani M, Lundqvist A, Betsholtz C, Brownlee M and Deutch U.** Pericytes and the pathogenesis of diabetic retinopathy. *Diabetes.* 2002; 51: 3107–3112.
- 93.**Han DP, Nash RW, Blair JR, O'Brien WJ and Medina RR.** Comparison of scleral tensile strength after transscleral retinal cryopexy, diathermy, and diode laser photocoagulation. *Arch Ophthalmol.* 1995; 113:1195–1199.
- 94.**Han SK, Park Kh, Kim DM and Chang BL.** Effect of diode laser trans-scleral cyclophotocoagulation in the management of glaucoma after intravitreal silicone oil injection for complicated retinal detachment. *Br J Ophthalmol.* 1999; 83:713–717.
- 95.**Hayreh, S.S.** The Cilio-Retinal Arteries. *Br. J. Ophthalmol.* 1963; 47, 71–89.
- 96.**Hee MR, Puliafito CA, Duker JS, Reichel E, Cocker JG, Wilkins JR., Schuman JS, Swanson EA. and Fujimoto JG.** Topography of diabetic macular oedema with optical coherence tomography. *Ophthalmol.* 1998; 105: 360-370.

References

97. **Hee MR, Puliafito CA, Wong C, et al.** Optical coherence tomography of macular holes. *Ophthalmology*. 1995; 102:748-756.
98. **Helbig H, Kellner U, Bornfeld N and Foerster MH.** Vitrektomie bei diabetischer Retinopathie: Ergebnisse, Risikofaktoren, Komplikationen. *Klin Monatsbl Augenheilkd* 1998; 212(5):339–342.
99. **Henkind P. and De Oliveira L.F.** Development of the retina vessels in the rat. *Invest. Ophthalmol. Vis. Sci.* 1967a; 6, 520–523.
100. **Henkind P. and De Oliveira L.F.** New observations on the radial peripapillary capillaries. *Invest. Ophthalmol. Vis. Sci.* 1967b; 6, 103–108.
101. **Hernandez C, Carrasco E, Garcia-Arumi J, Maria Segera R and Simo.** Intravitreal levels of hepatocyte growth factor / scatter factor and vascular adhesion molecule-1 in the vitreous fluid of diabetic patients with proliferative retinopathy. *Diabetes Metab.* 2004; 30: 341–346.
102. **Hewick S, Lois N and Olson JA.** Circumferential peripheral retinal cavernous hemangioma. *Arch Ophthalmol.* 2004; 122: 1557–1560.
103. **Ho T, Smiddy WE and Flynn HWJ.** Vitrectomy in the management of diabetic eye disease. *Surv Ophthalmol.* 1992; 37: 190–202.
104. **Hogan M J and Alvarado JA.** Histology of human eye. Philadelphia Sunders 1st ed. 1971; 393-396.
105. **Hyang SM and Kim SK.** Mid-term effects of trabeculectomy with mitomycin C in neovascular glaucoma patients. *Korean J Ophthalmol.* 2001; 15:98–106.
106. **Irvine F, O'Donnell N, Kemp E and Lee WR.** Retinal vasoproliferative tumors: surgical management and histological findings. *Arch Ophthalmol.* 2000; 118:563–569.
107. **Itakura H, Kishim S, Kotajima N and Murakami M.** Persistent secretion of vascular endothelial growth factor into the vitreous cavity in

References

- proliferative diabetic retinopathy after vitrectomy. *Ophthalmology*. 2004; 111:1880–4.
108. **Izatt JA, Hee MR, Swanson EA, et al.** Micrometer -scale resolution imaging of the anterior eye in vivo with optical coherence tomography. *Arch Ophthalmol*. 1994; 112: 1584-1589.
109. **Jain K, Berger AR, Yucil YH and McGowanHD.** Vasoproliferative tumours of the retina. *Eye*. 2003; 17:364–368.
110. **Jandeck C. and Foerster M. H.** Retinopathy of Prematurity: Clinical Course and Treatment. In *Retinal Vascular Disease*. A.M. Jousseaume · T.W. Gardner · B. Kirchhof · S.J. Ryan (Eds.) 2007; Ch. 20.2:403-417.
111. **John Timothy Stout.** GENE TRANSFER FOR THE TREATMENT OF NEOVASCULAR OCULAR DISEASE. *Am Ophthalmol Soc*. 2006; December 104:530-560.
112. **Jonas JB, Degenring RF, Kreissig I, Akkoyun I and Kamppeier BA.** Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. *Ophthalmology*. 2005; 112: 593–598.
113. **Jonas JB, Hayler JK, Sofker A and Panda-Jonas S.** Regression of neovascular iris vessels by intravitreal injection of crystalline cortisone. *J Glaucoma*. 2001; 10:284–287.
114. **Jousseaume A. M and Kirchhof B.** Solitary peripapillary hemangioblastoma. A histopathological case report. *Acta Ophthalmol Scand*. 2001; 79:83–87.
115. **Jousseaume A. M. and Kirchhof B.** Vitrectomy in Retinal Vascular Disease: Surgical Principles. In *Retinal Vascular Disease*. A.M. Jousseaume · T.W. Gardner · B. Kirchhof · S.J. Ryan (Eds.) 2007; Ch. 16:260-273.
116. **Jousseaume AM., Walter P., Jonescu-Cypers CP., Koizumi K., Poulaki V., Bartz-Schmidt KU., Krieglstein GK. and Kirchhof B.** Retinectomy for

References

- treatment of intractable glaucoma. Long term results. Br J Ophthalmol. 2003; 87:1094–1103.
117. **Jurklies B. and Bornfeld N.** The Role of Photodynamic Therapy in Retinal Vascular Disease. In Retinal Vascular Disease. A.M. Jousseaume · T.W. Gardner · B. Kirchhof · S.J. Ryan (Eds.) 2007; Ch. 14:239-255.
118. **Kaiser PK.** Verteporfin photodynamic therapy and anti-angiogenic drugs: potential for combination therapy in exudative age-related macular degeneration. Curr Med Res Opin 2007; 23 (3): 477-487
119. **Kakarija A and Soff G.** Up date on angiogenesis inhibitors. Curr Opin Oncol 2005 Nov; 17(6):578-583.
120. **Kanski J and Milewski SA.** Diseases of the macula: Practical approach. Mosby 1st ed. 2002; ch.1:53-60.
121. **Kanski J J.** Clinical ophthalmology. A systemic approach. Butterworth-Heinemann, Linacre House, Jordam Hill, Oxford. 4th ed. 1999; ch.10: 395-436.
122. **Keith CG.** Visual outcome and effect of treatment in stage III developing retrolental fibroplasia. Br J Ophthalmol. 1982; 66:446–449.
123. **Kerbel R and Folkman J.** Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2002; 2:727-739.
124. **Kirchhof B. and Jousseaume A.M.** Cryosurgery in Retinal Vascular Disease. In Retinal Vascular Disease. A.M. Jousseaume · T.W. Gardner · B. Kirchhof · S.J. Ryan (Eds.) 2007; Ch. 14:239-255.
125. **Klein R and Klein B.** Vision disorders in diabetes. In: Group NDD, ed. Diabetes in America. 2 ed. Washington, D.C.: National Institutes of Health. 1995; 294.
126. **Klein R, Knudtson MD, Lee KE, Gangnon R and Klein BE.** The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the

References

- twenty-five-year incidence of macular edema in persons with type 1 diabetes. *Ophthalmology*. Mar 2009;116(3):497-503.
127. **Ko TH, Fujimoto JG, Duker JS, et al.** Ultrahigh and standard resolution OCT of Macular Hole. *Ophthalmology*. 2004; 111: 2033 – 2043.
128. **Kobayashi N, Kabuyama Y, Sasaki S, et al.** Suppression of corneal neovascularization by culture supernatant of human amniotic cells. *Cornea*. 2002; 21:62–67.
129. **Kollias A N and Ulbig M W.** Diabetic Retinopathy: Early Diagnosis and Effective Treatment, *Dtsch Arztebl Int* 2010; 107(5): 75-84.
130. **Kremer I, Cohen EJ, Eagle RC Jr, et al.** Histopathologic evaluation of stromal inflammation in *Acanthamoeba keratitis*. *CLAO J*. 1994; 20:45-48.
131. **Kristinsson JK, Stefansson E, Jonasson F, et al.** Systematic screening for diabetic eye disease in insulin dependent diabetes. *Acta Ophthalmol*. 1994; 72:72-78.
132. **Krzystolik MG, Afshari MA, Adamis AP, Gaudreault J Gragoudas ES, Michaud NA, Li W, Connolly E, O'Neill CA and Miller JW.** Prevention of experimental neovascularization with intravitreal injection of anti-vascular endothelial growth factor antibody fragment. *Arch Ophthalmol* 2002; Mar 120(3): 338 - 346.
133. **Kuang TM, Liu CJ, Chou CK and HsuWM.** Clinical experience in the management of neovascular glaucoma. *J Chin Med Assoc*. 2004; 67:131–5.
134. **Kuppersmann BD, Williams GA, Blumenkranz MS, et al.** Efficacy and safety of a novel intravitreal dexamethasone drug-delivery system after applicator or incisional placement in patients with macular edema. Program and abstracts of the Association for Research in Vision and

References

- Ophthalmology; April 30-May 4, 2006; Fort Lauderdale, Florida. Abstract 5913.
135. **Lang GE.** Diabetic retinopathy. *Developments in ophthalmology.* 2007; 39:31-47.
136. **Laqua H and Wessing A.** Peripheral retinal telangiectasis in adults simulating a vascular tumor or melanoma. *Ophthalmology.* 1983; 90:1284–1291.
137. **Lashkari K, Hirose T, Yazdany J, McMeel JW, Kazlauskas A and Rahimi N.** Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity. *Am J Pathol.* 2000; 156: 1337–1344.
138. **Lavaque AJ, Esteban JL, Yilmaz T and Liggett P.** Exudative age related macular degeneration-Part-1. Pharmacological Inhibition of Vascular Endothelial Growth Factor. *Highlights of Ophthalmology.* 2005; 33(4):9-11.
139. **Lee C M and Olk R J.** Modified grid laser photocoagulation for diffuse diabetic macular edema. Long term results. *Ophthalmology.* 1991; 98: 1594- 1602.
140. **Leibovitch I, Loewenstein A, Alster Y, et al.** Interferon alpha-2a for proliferative diabetic retinopathy after complete laser panretinal photocoagulation treatment. *Ophthalmic Surg Lasers Imaging.* 2004; 35:16-22.
141. **Leung AK, Weisbrod DJ and Schwartz C.** Intravitreal ranibizumab in the treatment of choroidal neovascular membrane secondary to punctate inner choroidopathy, *Can J Ophthalmol.* Jun 2010;45(3):1-2.

References

142. **Leung DW, Cachianes G, Kuang WJ, Goeddel DV and Ferrara N.** Vascular endothelial growth factor is a secreted angiogenic mitogen. *Science*. 1989; 246: 1306- 1309.
143. **Licy Y, Shan S, Huag Q, Braun R D, Lanzen J and Hu K.** Initial stages of tumour cell-induced angiogenesis. Evaluation via skin window chambers in rodent models. *J Natl Cancer inst*. 2000; 92: 143-147.
144. **Liesegang TJ.** Physiologic changes of the cornea with contact lens wear. *CLAO J* 2002; 28(1): 12-27.
145. **Lipman RM, Epstein RJ and Hendricks RL.** Suppression of corneal neovascularization with cyclosporine. *Arch Ophthalmol*. Mar. 1992; 110 (3): 405-407.
146. **Lu M, Kuroki M, Amano S, et al.** Advanced glycation end products increase retinal vascular endothelial growth factor expression. *J Clin Invest*. 1998; 101:1219-1224.
147. **Maas S, Deutman AF, Bandhoe F, Aaderkerk AL.** Surgical removal of subretinal neovascular membrane. *Eur. J. Ophthalmol*. 1995; 5, 48-55.
148. **Machemer R and Williams JM Sr.** Pathogenesis and therapy of traction detachment in various retinal vascular diseases. *Am J Ophthalmol*. 1998; 105:170–181.
149. **Maher ER, Webster AR and Moor AT.** Clinical features and molecular genetics of von Hippel-Lindau disease. *Ophthalmol Genet*. 1995; 16:79–84.
150. **Malecaze F , Clamens S , Mathis A , Chollet P , Favard C , Bayard F and Plouet J.** Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. *Arch Ophthalmol*. 1994; 112: 1476-1482.

References

151. **Malecha MA, Haik BG, Morris WR.** Capillary hemangioma of the optic nerve head and juxtapapillary retina. *Arch Ophthalmol.* 2000; 118:289–291.
152. **Mandal AK, Majji AB, Mandal SP, Das T, Jalali S, Gothwal VK, Jain SS and Nutheti R.** Mitomycin-C augmented trabeculectomy for neovascular glaucoma. A preliminary report. *Indian J Ophthalmol.* 2002; 50:287–293.
153. **Mandarino LJ.** Current hypothesis for biochemical basis of diabetic retinopathy. *Diabetes Care.* 1992; 15:1892-1901.
154. **Mantagos IS, Vanderveen DK and Smith LE.** Emerging treatments for retinopathy of prematurity. *Semin Ophthalmol.* 2009; Mar-Apr 24(2):82-86.
155. **Marano RJ, Toth I, Wimmer N, Brankov μ and Rakoczy PE.** Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: a long term study into inhibition of laser-induced choroidal neovascular membrane, distribution, uptake and toxicity. *Gene Ther* 2005 Nov; 12(21):1544-1550.
156. **Marrison RS and Yahanda MA.** Tumour angiogenesis and the role of paracrine mediators. In Emil F and Sanford AS. *Molecular basis of Oncology.* Blackwell Science. 1998; Ch.6: 171-179.
157. **Marshall J, Clover G and Rothery S.** Some new findings of retinal irradiation by krypton and argon lasers. In: Birngruber R, Gabel V-P (eds) *Laser treatment and photocoagulation of the eye.* Junk Publ. The Hague. 1984; pp 21–37.
158. **Marticorena J, Gomez-Ulla F, Fernandez M, Pazos B, Rodriguez-Cid MJ, Sanchez-Salorio M.** Combined photodynamic therapy and intravitreal triamcinolone acetonide for the treatment of myopic subfoveal choroidal neovascularization. *Am. J. Ophthalmol.* 2006; 142(2), 335-337.

References

159. **Martin KR and Broadway DC.** Cyclodiode laser therapy for painful, blind glaucomatous eyes. *Br J Ophthalmol.* 2001; 85: 474–6.
160. **Mc Millan DE.** The effect of diabetes on blood flow properties. *Diabetes.* 1993; 32 (Suppl 2): 56 - 63.
161. **McCabe CM, Flynn HW Jr, Shields CL et al.** Juxtapapillary capillary hemangiomas. Clinical features and visual acuity outcomes. *Ophthalmology.* 2000; 107:2240–2248.
162. **McDonald DM and Choyke PL.** Imaging of angiogenesis: from microscope to clinic. *Nat Med* 2003; 9:713–725.
163. **McGee GS, Davidson JM, Buckley A, Sommer A, Woodward SC, Aquino AM, Barbour R and Demetriou AA.** Recombinant basic fibroblast growth factor accelerates wound healing. *J Surg Res.* 1988; 45:145–153.
164. **MermoudA, Salmon JF, Alexander P, Straker C and MurrayAD.** Molteno tube implantation for neovascular glaucoma. Long-term results and factors influencing the outcome. *Ophthalmology.* 1993; 100:897–902.
165. **Michael AZ, Caig HS, and Aden H.** Surgical implications of therapeutic angiogenesis. *Surgery.* 1999; (125) 3: 243 - 249.
166. **Mietz H, Raschka B and Krieglstein GK.** Risk factors for failures of trabeculotomies performed without antimetabolites. *Br J Ophthalmol.* 1999; 83:814–821.
167. **Miller JW, Adamis AP and Aiello LP.** Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. *Diabetes / Metabolism Rev.* 1997; 13: 37-50.
168. **Mintz-Hittner HA and Kuffel RR Jr.** Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. *Retina.* 2008; Jun 28(6):831-838.

References

169. **Mistlberger A, Liebmann JM, Tschiderer H, Ritch R, Ruckhofer J and Grabner G.** Diode laser transscleral cyclophotocoagulation for refractory glaucoma. *J Glaucoma*. 2001; 10:288–293.
170. **Mizutani M, Kern TS and Lorinzi M.** Accelerated death of retinal neovascular cells in human and experimental diabetic retinopathy. *J Clin Invest*. 1996; 97: 1883-1890.
171. **Mousa S A.** Mechanisms of Angiogenesis: Potential Therapeutic Targets. In: *Angiogenesis Inhibitors and Stimulators: Potential Therapeutic Implications*. Mousa S A. 1 st ed. Eureka.com / Landes Bioscience. Texas, U.S.A. 2000; pp 1-12.
172. **Muller VA, Ruokonen P, SchellenbeckM, Hartmann C and Tetz M.** Treatment of rubeosis iridis with photodynamic therapy with verteporfin – A new therapeutic and prophylactic option for patients with risk of neovascular glaucoma. *Ophthalmic Res*. 2003; 35:60–64.
173. **Nabili S and Kirkness CM.** Trans-scleral diode laser cyclophotocoagulation in the treatment of diabetic neovascular glaucoma. *Eye*. 2004; 18:352–356.
174. **Nagata M and Takishima R.** One side of the coin of functions of public health nursing – with the establishment of home care helpers. *Kango*. 1968; 20:130–134.
175. **Nahoko O, Maki N, Tetsuy A N, Yumiko M and Miyo M.** Unbalanced vitreous levels of pigment epithelium derived factor and vascular endothelial growth factor in diabetic retinopathy. *Am J Ophthalmology*. 2002; 134 (3): 348-353.
176. **National Eye Institute Web site.** Retinopathy of Prematurity (ROP). Last modified Oct 2006. www.nei.nih.gov/health/rop/index.asp. (Accessed 11 October 2006.)

References

177. **Ng YK, Fielder AR, Shaw DE and Levene MI.** Epidemiology of retinopathy of prematurity. *Lancet*. 1988; 2:1235–1238.
178. **Nguyen QD, Shah SM, Van Anden E, et al.** Supplemental oxygen improves diabetic macular edema: a pilot study. *Invest Ophthalmol Vis Sci*. 2004; 45:617-624.
179. **Noma H , Funatsu H , Yamashita H , Kitano S , Mishima HK and Hori S.** Regulation of angiogenesis in diabetic retinopathy. Possible balance between vascular endothelial growth factor and endostatin. *Arch Ophthalmol*. 2002; 120:1075-1080.
180. **Ogata N, Ando A, Uyama M and Matsumura M.** Expression of cytokines and transcription factors in photocoagulated human retinal pigment epithelial cells. *Graefes Arch Clin Exp Ophthalmol*. 2001; 239:87–95.
181. **Ogata N, Tombran-Tink J, Jo N, Mrazek D and Matsumura M.** Upregulation of pigment epithelium-derived factor after laser photocoagulation. *Am J Ophthalmol*. 2001; 132:427– 429.
182. **Ohnishi Y, Ishibashi T and Sagawa T.** Fluorescein angiography in diabetic neovascularisation. *Graefes Arch Clin Exp Ophthalmol*. 1994; 232:199–204.
183. **Ohno-Matsui K, Morishima N, Ito M et al.** Indocyanine green angiographic findings of lacquer cracks in pathological myopia. *Jpn J. Ophthalmol*. 1998; 42, 293-299.
184. **Olk R J and Lee C M.** Diabetic retinopathy: Practical management. Lippincott Company, Philadelphia 1st ed. 1993; ch.2: 3 -20.
185. **Oreilly M, Boehm T, Shing Y, Vasios G and Lane W.** Endostatin an endogenous inhibitor of angiogenesis and tumour growth. *Cell*. 1997; 88: 277-285.

References

186. **Oshima Y, Oshima S, Nambu H et al.** Different effects of angiopoietin-2 in different vascular beds. New vessels are most sensitive. *FASEB J.* 2005; 19: 963–965.
187. **Ozdamar A, Aras C and Karacorlu M.** Suprachoroidal seton implantation in refractory glaucoma. A novel surgical technique. *J Glaucoma.* 2003; 12:354–359.
188. **Ozdek S, Hondur A, Gurelik G, Hasanreisoglu B.** Transpupillary thermotherapy for myopic choroidal neovascularization: 1-year follow-up: TTT for myopic CNV. *Int. Ophthalmol.* 2005; 26(4-5), 127-133.
189. **Palmer JD and Gragoudas ES.** Advances in treatment of retinal angiomas. *Int Ophthalmol Clin.* 1997; 37:150–170.
190. **Pancurak J, Goldberg MF, Frenkel M and Crowell RM.** Cavernous hemangioma of the retina. Genetic and central nervous system involvement. *Retina.* 1985; 5:215–220.
191. **Pe'er J, Shweiki D, Itin A, Hemo J, Gnessin H and Keshet E.** Hypoxia induced expression of Vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. *Lab Invest.* 1995; 72: 638-645.
192. **Pearson P, Levy B and Comstock T,** Fluocinolone Acetonide Implant Study Group. Fluocinolone acetonide intravitreal implant to treat diabetic macular edema: 3-year results of a multi-center clinical trial. Program and abstracts of the Association for Research in Vision and Ophthalmology; April 30-May 4, 2006; Fort Lauderdale, Florida. Abstract 5442.
193. **Primbs GB, Casey R, Wamser K, et al.** Photodynamic therapy for corneal neovascularization. *Ophthalmic Surg Lasers.* 1998; 29: 832–838.
194. **Puliafito CA, Hee MR, Schuman JS and Fujimoto JG.** “Principles of operation and technology” in “Optical coherence tomography of ocular

References

- diseases". Salk Incorporated, 6900 Grove Road, Thorofare, USA. 1996; Ch.1, P.3-15.
195. **Pulido J S.** Retina, Choroid, and Vitreous. Mosby Inc 2nd ed. 2002; ch.4: 31-32.
196. **Qian CX, Bahar I, Levinger E and Rootman D.** Combined use of superficial keratectomy and subconjunctival bevacizumab injection for corneal neovascularization. *Cornea*. Oct 2008; 27(9):1090-1092.
197. **Rafael S, Albert L, Rosa MS, Jose GA and Cristina H.** Free insulin growth factor –I and Vascular endothelial growth factor in vitreous fluid of patients with proliferative diabetic retinopathy . *Am J Ophthalmol*. 2002; 134 (3): 376-382.
198. **Raju TN, Langenberg P, Bhutani V and Quinn GE.** Vitamin E prophylaxis to reduce retinopathy of prematurity: a reappraisal of published trials. *J Pediatr*. 1997; 131:844–850.
199. **Rednam KRV, Jampol LM and Goldberg MF.** Scatter retinal photocoagulation for proliferative sickle cell retinopathy. *Am J Ophthalmol* 1982; 93:594-599.
200. **Rehak J.** Rubeosis iridis and neovascular glaucoma. I. Etiopathogenesis and treatment the present state of the problem. *Acta Univ Palack Olomuc Fac Med*. 1992; 134:101–103.
201. **Rogers AH and Witkin A.** Neovascular age-related macular degeneration. In: *Retinal imaging*, Mo: Mosby. 2006; 152–163.
202. **Rosenfeld PJ, Brown DM, Heier JS et al.; MARINA Study Group.** Ranibizumab for neovascular age-related macular degeneration. *N. Engl. J. Med.* 2006; 355(14), 1419-1431.
203. **Rosenfeld PJ, Schwartz DS Blumenkranz MS, Miller JW, Haller JA, Reimann JD, Greene WL and Shams N.** Maximum tolerated dose of a humanized anti – VEGF antibody fragment for treating neovascular age-

References

- related macular degeneration. *Ophthalmology* 2005 Jun; 112 (6):1048-1053.
204. **Rüfer F. and Roider J.** General Concepts in Laser Treatment for Retinal Vascular Disease. In *Retinal Vascular Disease*. A.M. Joussen · T.W. Gardner · B. Kirchhof · S.J. Ryan (Eds.) 2007; Ch. 13:228-238.
205. **Rummelt V, Mehaffey MG, Campbell RJ, et al.** Microcirculation architecture of metastases from primary ciliary body and choroidal melanomas. *Am J Ophthalmol.* Aug 1998;126(2):303-5.
206. **Rungger-Brandle E., Messerli J.M., Niemeyer G. and Eppenberger H.M.** Confocal microscopy and computer-assisted image reconstruction of astrocytes in the mammalian retina. *Eur. J. Neurosci.* 1993; 5, 1093–1106.
207. **Ryan SJ.** Subretinal neovascularization, in Ryan SJ (Ed): *Retina*. St Louis, CV Mosby. 1989; pp 107–125.
208. **Saishin Y, Saishin Y, Takahashi K, et al.** Inhibition of protein kinase C decreases prostaglandin-induced breakdown of the blood-retinal barrier. *J Cell Physiol.* 2003; 195:210-219.
209. **Sall JW, Klisovic D, O'Dorisio M and Katz SE.** Somatostatin inhibits Insulin growth factor –1 mediated induction of Vascular endothelial growth factor in human retinal pigment epithelial cells. *Exp Eye Res.* 2004; 79:465-476.
210. **Sawa M, Awazu K, Takahashi T, et al.** Application of femtosecond ultrashort pulse laser to photodynamic therapy mediated by indocyanine green. *Br J Ophthalmol.* Jun 2004; 88(6):826-831.
211. **Schlote T, Derse M, Rassmann K, Nicaeus T, Dietz K and Thiel H-J.** Efficacy and safety of contact transscleral diode laser cyclophotocoagulation for advanced glaucoma. *J Glaucoma.* 2001; 10:294–301.

References

212. **Schlote T, Ziemssen F and Bartz-Schmidt KU.** Pars plana modified Ahmed Glaucoma Valve for treatment of refractory glaucoma. A pilot study. *Graefes Arch Exp Clin Ophthalmol.* 2006; 244(3):336–341.
213. **Schlote T. and Bartz-Schmidt K.U.** Treatment of Rubeotic Secondary Glaucoma. In *Retinal Vascular Disease.* A.M. Joussen · T.W. Gardner · B. Kirchhof · S.J. Ryan (Eds.) 2007; Ch. 17:274-282.
214. **Scholer F.** Experimentelle Erzeugung von Aderhaut- Netzhautentzündung durch Kohlensaureschnee. *Klin Monatsbl Augenheilkd.* 1918; 60:61.
215. **Seitz B, Gruterich M, Cursiefen C and Kruse FE.** Konservative und chirurgische Behandlung der neurotrophen Keratopathie. *Ophthalmologe.* 2005; 102:15–26.
216. **Seizinger BR, Rouleau GA and Ozelius LJ.** Von Hippel- Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. *Nature.* 1988; 332:268–269.
217. **Senger DR, Galli SJ and Drorak MA.** Tumor cells secrete a vascular permeability factor that promotes accumulation of ascitis. *Science.* 1983; 219: 983-985.
218. **Shields CL, Shields JA, Baez K, Cater JR and De Potter P.** Optic nerve invasion of retinoblastoma. *Cancer.* 1995; 73:692–698.
219. **Shono T, OnoM, IzumiH, Jimi SI, MatsushimaK, Okamoto T, Kohno K and Kuwano M.** Involvement of the transcription factor NF-kappaB in tubular morphogenesis of human microvascular endothelial cells by oxidative stress. *Mol Cell Biol.* 1996; 16:4231–4239.
220. **Sihota R, Sandramouli S and Sood NN.** A prospective evaluation of anterior retinal cryoablation in neovascular glaucoma. *Ophthalmic Surg.* 1991; 22:256–259.
221. **Singh AD, Nouri M, Shields CL, Shields JA and Perez N.** Treatment of retinal capillary hemangioma. *Ophthalmology.* 2002; 109:1799–1806.

References

- 222. **Sivagnavel V, Ortiz-Hurtado A and Williamson TH.** Diode laser trans-scleral cyclophotocoagulation in the management of glaucoma in patients with long term intravitreal silicone oil. *Eye*. 2005; 19:253–257.
- 223. **Stewart WC and Emkin J.** Pharmacological treatment of age related macular degeneration. *Adv Drug Deliv Rev* 2005 Nov 22.
- 224. **Stolle C, Glenn G, Zbar B, et al.** Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. *Hum Mutat*. 1998; 12:417–423.
- 225. **Strom C, Sander B, Klemp K, et al.** Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema. *Invest Ophthalmol Vis Sci*. 2005; 46:3855-3858.
- 226. **Takagi H, Koyama S, Seike H, Oh H, Otani A, Matsumura M and Honda Y.** Potential role of the angiopoietin / Tie-2 system in ischaemia-induced retinal neovascularization. *Invest Ophthalmol Vis Sci*. 2003; 44: 393–402.
- 227. **Takeda AL, Colquitt J, Clegg AJ, Jones J.** Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review. *Br J Ophthalmol*. 2007; 91:1177-1182.
- 228. **The Eyetech Study Group.** Anti vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age related macular degeneration, Phase II Study results. *Ophthalmology* 2003; 110(5): 979-986.
- 229. **The Eyetech Study Group.** Preclinical and phase 1A Clinical evaluation of an anti-vascular endothelial growth factor pegylated aptamer (EYE 001) for treatment of exudative age related macular degeneration. *Retina* 2002; 22(2) :143-152.
- 230. **The PKC-DRS Study Group.** The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic

References

- retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. *Diabetes*. 2005; 54:2188-2197.
231. **Tolentino MJ, Miller JW and Gragoudas ES.** Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in non human primate. *Arch Ophthalmol*. 1996; 114: 964 – 970.
232. **UK Prospective Diabetes Study Group.** Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38), *BMJ*. 1998; 317:703-713.
233. **Wakelee HA and Schiller JH.** Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors. *Clin Lung Cancer* 2005 Sep; Suppl 1:31-38.
234. **Weich H, Iberg N, Klagsbrum M and Folkman J.** Expression of acidic and basic fibroblast growth factors in human and bovine vascular smooth muscle cells. *Growth factors*. 1990; 2: 313-320.
235. **Wilkinson-Berka JL, Babic S, De Gooyer T, Stitt AW, Jaworski K, Ong LG, Kelly DJ and Gilbert RE.** Inhibition of platelet derived growth factor promotes pericyte loss and angiogenesis in ischaemic retinopathy. *Am J Pathol*. 2004; 164: 1263–1273.
236. **Wilson AS, Hobbs BG, Shen WY, Speed TP, Schmidt U, Begley CG and Rakoczy PE.** Argon laser photocoagulation- induced modification of gene expression in the retina. *Invest Ophthalmol Vis Sci*. 2003; 44:1426–1434.
237. **Wise G.N., Dollery C.T. and Henkind P.** *The Retinal Circulation*. Harper and Row, New York. 1975; pp. 20–82.

References

- 238. **Witmer A.N., Vrensen G.F., VanNoorden C.J. and Schlingemann R.O.** Vascular endothelial growth factors and angiogenesis in eye disease. *Progress in Retinal and Eye Research*. 2003; 22, 1–29.
- 239. **Wolbarsht ML, Landers MB and Stefansson E.** Vasodilatation and the etiology of diabetic retinopathy. A new model. *Ophthalmic Surg*. 1981; 12:104–107.
- 240. **Yamaguchi K, Yamaguchi K and Tamai M.** Cavernous hemangioma of the retina in the pediatric patient. *Ophthalmologica*. 1988; 197:127–129.
- 241. **Yamashita Y.** Studies on retinopathy of prematurity. III. Cryocautery for retinopathy of prematurity. *Rinsho Ganka*. 1972; 26:385–393.
- 242. **Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ and Holash J.** Vascular- specific growth factors and blood vessel formation. *Nature*. 2000; 407: 242–248.
- 243. **Yoshida T, Ohno-Matsui K, Ohtake Y et al.** Long-term visual prognosis of choroidal neovascularization in high myopia. A comparison between age groups. *Ophthalmology*. 2002; 109, 712-719.
- 244. **Zhang SX and Ma JX.** Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapy. *Prog Retin Eye Res* 2007; 26(1): 1-37.
- 245. **Zhang, Y. and Stone, J.** Role of astrocytes in the control of developing retinal vessels. *Invest. Ophthalmol. Vis. Sci*. 1997; 38, 1653–1666.
- 246. **Zheng M, Schwarz MA, Lee S, et al.** Control of stromal keratitis by inhibition of neovascularization. *Am J Pathol* 2001; 159(3): 1021- 1029.
- 247. **Zimmerman M, Selzman H and Horken A.** Therapeutic angiogenesis. *Surgery*. 1999; Mar 125(3):244-248.